This Article Full Text Full Text (PDF) All Versions of this Article: 106/17/2238    most recent 01.CIR.0000035241.76918.6Cv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Diedrich, A. Articles by Biaggioni, I. Search for Related Content PubMed PubMed Citation Articles by Diedrich, A. Articles by Biaggioni, I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Autonomic Nervous System Disorders Related Collections Electrocardiology

(Circulation. 2002;106:2238.)
© 2002 American Heart Association, Inc.

Clinical Investigation and Reports

Modulation of QT Interval During Autonomic Nervous System Blockade in Humans

From the Autonomic Dysfunction Center, Vanderbilt University, Nashville, Tenn (A.D., J.R.S, D.R., I.B.), and the Clinical Research Center, Franz Volhard Clinic, Berlin, Germany (J.J.).

Correspondence to André Diedrich, MD, PhD, Autonomic Dysfunction Center, AA3228 MCN, Vanderbilt University, Nashville, TN 37232-2195. E-mail andre.diedrich{at}vanderbilt.edu

Background— It is thought that the autonomic nervous system modulates QT interval, but traditional autonomic blockade combining propranolol and atropine has produced conflicting results. We used the alternative approach of interrupting neurotransmission at the level of autonomic ganglia to determine its effect on the QT interval.

Methods and Results— We infused trimethaphan at increasing doses (0.5 to 10 mg/min IV) while monitoring heart rate, heart rate variability spectra, QT interval, and blood pressure in 10 normal volunteers, 9 patients with multiple system atrophy (MSA), and 8 patients with pure autonomic failure (PAF). The QT interval was corrected for heart rate using Bazett’s formula (QTc). Patients with PAF had very low heart rate variability and a prolonged QTc at baseline (465±8 ms) compared with patients with MSA (448±6 ms) and normal subjects (432±6 ms). In normal subjects, trimethaphan dose-dependently prolonged QTc (to 469±7 ms), decreased RR interval (995±45 to 670±35 ms), and abolished heart rate variability. In MSA patients, trimethaphan also prolonged QTc (to 463±7 ms) and reduced heart rate variability but did not significantly change RR interval (from 813±38 to 801±39).

Conclusions— Autonomic blockade prolongs QT interval in normal subjects to a similar duration as in PAF patients. Furthermore, blocking residual autonomic tone in PAF patients is associated with a further increase in QT interval length. Patients with MSA have greater residual sympathetic tone and greater prolongation of the QT interval during ganglionic blockade than PAF patients.

Key Words: nervous system, autonomic • trimethaphan • spectrum analysis

This article has been cited by other articles:

				B. Darpo, T. Nebout, and P. T. Sager Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline. J. Clin. Pharmacol., May 1, 2006; 46(5): 498 - 507. [Abstract] [Full Text] [PDF]

				C. Shibao, A. Gamboa, A. Diedrich, and I. Biaggioni Management of Hypertension in the Setting of Autonomic Failure: A Pathophysiological Approach Hypertension, April 1, 2005; 45(4): 469 - 476. [Abstract] [Full Text] [PDF]

				I. Biaggioni Autoimmune Ganglionic Blockade. A Cause of Autonomic Failure. Focus on "Experimental Autoimmune Autonomic Neuropathy" J Neurophysiol, September 1, 2003; 90(3): 1377 - 1378. [Full Text] [PDF]